Home > Groups > Baverian Nordic Case Study

Baverian Nordic Case Study

Recently Added Items

Title	Added By	Updated On
Temperature-sensitive miR-483 is a conserved regulator of recombinant protein and viral vector production in mammalian cells	Jeff_Che	May 11, 2016 4:19:25 AM
CHO microRNA engineering is growing up: Recent successes and future challenges	Jeff_Che	May 11, 2016 4:06:02 AM
MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells	Jeff_Che	May 11, 2016 3:57:28 AM
Buffeted by headwinds, Bavarian Nordic cancels IPO \| FierceBiotech	Jeff_Che	May 6, 2016 9:18:52 AM
After ditching its IPO, Bavarian Nordic gains private placing \| FierceBiotech	Jeff_Che	May 6, 2016 9:18:48 AM
Monday Morning	Jeff_Che	May 6, 2016 8:59:17 AM
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer	m_gaddis	May 6, 2016 6:48:28 AM
The global burden of cancer: priorities for prevention	m_gaddis	May 6, 2016 6:43:30 AM
FDA APPROVES IMLYGICTM (TALIMOGENE LAHERPAREPVEC) AS FIRST ONCOLYTIC VIRAL THERAPY IN THE US	m_gaddis	May 6, 2016 6:41:19 AM
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors	m_gaddis	May 6, 2016 6:35:37 AM

See all 54 items for this group in the Group Library.